Verily launches joint venture for ophthalmology innovation

Andrea Park - Print  | 

Verily, the life sciences offshoot of Alphabet, has partnered with ophthalmology-focused Santen Pharmaceuticals to establish a joint venture to develop and commercialize new digital tools to improve eye health.

Through the joint venture, the two organizations will apply microelectronics, machine learning and other digital technologies to the development of connected ophthalmic devices and tech solutions that will offer more preventive and proactive options for eye care, according to a Feb. 4 news release sent to Becker's Hospital Review.

"Our focus is first and foremost on taking care of patients. By combining Santen's expertise and Verily's advanced technology, our joint venture is well-positioned to tackle innovative projects spanning ophthalmic conditions, such as glaucoma and dry eye. We'll explore ways to use technology not only to diagnose disease, but to improve treatment and develop more precise interventions in ophthalmology," Dimitri Azar, MD, senior director of ophthalmic innovation at Verily and CEO-designate of the joint venture, said in the release.

More articles on innovation:
HBR: 5 keys to success when crowdsourcing innovation
10 Arkansas providers recruit startups for 2nd annual digital health accelerator
What hospitals can learn from Airbnb to promote innovation: Dr. John Halamka discusses

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.